Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Chronic Renal Failure

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 10 articles:
HTML format

Single Articles

    December 2021
  1. GAUDRY S, Hajage D, Dechartres A, Quenot JP, et al
    Renal replacement therapy in acute kidney injury - Authors' reply.
    Lancet. 2021;396:1975-1976.

  2. LU Z, Yan P, Yang K, Yao L, et al
    Renal replacement therapy in acute kidney injury.
    Lancet. 2021;396:1974-1975.

  3. SEPE V, Rampino T, Libetta C
    Renal replacement therapy in acute kidney injury.
    Lancet. 2021;396:1974.

    June 2021
  4. KALANTAR-ZADEH K, Jafar TH, Nitsch D, Neuen BL, et al
    Chronic kidney disease.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00519.
    PubMed     Abstract available

    FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?
    Lancet. 2021 Jun 4. pii: S0140-6736(21)01242.

    April 2021
  6. LUYCKX VA, Harris DCH, Varghese C, Jha V, et al
    Bringing equity in access to quality dialysis.
    Lancet. 2021 Apr 15. pii: S0140-6736(21)00732.

  7. OSTERMANN M, Lumlertgul N
    Wait and see for acute dialysis: but for how long?
    Lancet. 2021;397:1241-1243.

  8. GAUDRY S, Hajage D, Martin-Lefevre L, Lebbah S, et al
    Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial.
    Lancet. 2021;397:1293-1300.
    PubMed     Abstract available

    September 2020
  9. FLOWER B, Atchison C
    SARS-CoV-2 antibody seroprevalence in patients receiving dialysis in the USA.
    Lancet. 2020 Sep 25. pii: S0140-6736(20)32006.

  10. ANAND S, Montez-Rath M, Han J, Bozeman J, et al
    Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study.
    Lancet. 2020 Sep 25. pii: S0140-6736(20)32009.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Renal Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.